StockData
Artiva Biotherapeutics, Inc. logo

Artiva Biotherapeutics, Inc. (ARTV) stock

ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.86−0.10 (-2.53%)

Close on Nov 17, 2026Market cap $188.72MP/E –Yield –

Earnings

Artiva Biotherapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 9, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q2 FY2025
–
EPS, Q2 FY2025
-$0.87
-$22.00 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Artiva Biotherapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 9, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Oct 27, 2026before the open–––Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026after the close–––Release
Q1 FY2026ended Mar 31, 2026May 8, 2026before the open–––Release
Q4 FY2025ended Dec 31, 2025Mar 10, 2026after the close–––Release
Q3 FY2025ended Sep 30, 2025Nov 12, 2025before the open–––Release
Q2 FY2025ended Jun 30, 2025Aug 6, 2025after the close––-$0.87Release
Q1 FY2025ended Mar 31, 2025May 8, 2025before the open––-$0.83Release
Q4 FY2024ended Dec 31, 2024Mar 24, 2025after the close–––Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024after the close$0–-$0.92Release
Q2 FY2024ended Jun 30, 2024Aug 29, 2024after the close$0–-$22.00Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Artiva Biotherapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Artiva Biotherapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Artiva Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?